Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway

Fig. 2

ZMIZ2 promotes the malignant biological behavior of SK-hep1 cells. (A) The mRNA expressions of ZMIZ2 were highly increased in SK-hep1 cell compared with immortalized LO2 human hepatocytes. (B) The efficiencies of ZMIZ2 silencing in SK-hep1 cell were validated by qRT-PCR. (C) The efficiencies of ZMIZ2 silencing in SK-hep1 cell were validated by Western blotting. (D-F) CCK8 assay, Luminescent Cell Viability Assay and EDU assays were performed to identify proliferation after ZMIZ2 knockdown in SK-hep1 cells. (G-H) Wound healing, migration, and invasion assays were performed to identify metastasis ability after ZMIZ2 knockdown in SK-hep1 cells. (I) Flow cytometry results showing the cell cycle distribution after ZMIZ2 knockdown in SK-hep1 cells. (J) Flow cytometry results showing the percentage of apoptotic cells after ZMIZ2 knockdown in SK-hep1 cells. *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001; ns, not significant

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us